Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 1, 2003 - Issue 4
Submit an article Journal homepage
7
Views
1
CrossRef citations to date
0
Altmetric
Review

Use of observational data in evaluating treatments: antiretroviral therapy and HIV

Azra C Ghani Department of Infectious Disease Epidemiology, Imperial College, Norfolk Place, London W2 1PG, UK. [email protected]
Pages 551-562 | Published online: 10 Jan 2014

References

  • Collier AC, Coombs RW, Schoenfield DA, et al Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl. J. Med. 334,1011–1017 (1996).
  • Cameron DW, Heath-Chiozzi M, Danner S, et al Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351,543–549 (1998).
  • Hammer SM, Squires KE, Hughes MD, et al A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl. J. Med. 337, 725–733 (1997).
  • Montaner JSG, Reiss P Cooper D, et al A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. JAIVIA 279,930–937 (1998).
  • Coombs RW, Welles SL, Hooper C, et al Association of plasma human immunodeficiency virus Type 1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174, 704–712 (1996).
  • Cascade Collaboration. Survival after introduction of HAART in people with known duration of HIV1 infection. Lancet 355,1158–1159 (2000).
  • Katzenstein DA, Hammer SM, Hughes MD, et al The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults. N. Erzgl. J. Med 335,1091–1098 (1996).
  • Marschner IC, Collier AC, Coombs RW, et al Use of changes in plasma levels of Human Immunodeficiency Virus Type 1 RNA to assess the clinical benefit of antiretroviral therapy. N Engl. J. Med. 177, 40–47 (1998).
  • Taylor S, Ferguson NM, Cane PA, Anderson RM, Pillay D. Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. AIDS 15,424 426 (2001).
  • Vemazza PL, Troiani L, Flepp MJ, et al Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 14,117–121 (2000).
  • Barroso PF, Schechter M, Gupta P, et al Effect of antiretroviral therapy on HIV shedding in semen. Ann. Intern. Med. 133, 280–284 (2000).
  • Yeni PG, Hammer SM, Carpenter CC, et al Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society — USA Panel. JAMA 288, 222–235 (2002).
  • Amberson JB, McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am. Rev. Tuberculosis 24, 401–435 (1931).
  • Delta Co-ordinating Committee. Arandomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 348,283–291 (1996).
  • Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine therapy in HIV infection. Arch. Intern. Med. 156,1073–1077 (1996).
  • CAESER Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection. Lancet 349, 1413–1421 (1997).
  • Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med 137,381–433 (2002).
  • Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States: analysis of a large observationaldatabase. HIV Med. 4,24–32 (2003).
  • Squires K, Johnson V, Katlama C, et al The Atlantic study: a randomized, open-label study to evaluate the efficacy and safety of three triple combination therapies aimed at different HIV targets in antiretroviral naive HIV-1 infected patients (final 48 weeksanalysis). 13th International AIDS conference, 14th July 2000, Durban, South Africa (2000).
  • Hirsch M, Steigbigel R, Staszewski S, et al A randomized, controlled trial of indinavir, zidovudine and lamivudine in adults with advanced Human Immunodeficiency Virus Type 1 infection and prior antiretroviral therapy. J. Infra. Dis. 180,659–665 (1999).
  • Chavanet P, Piroth L, Grappin M, et al Randomized salvage therapy with saquinavir—ritonavir versus saquinavir—nelfinavir for highly protease inhibitor-experienced HIV-infected patients. HIV Clin. Trials 2,408–412 (2001).
  • Gulick RM, Hu XJ, Fiscus SA, et al Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.j Infect. Dis. 186,626–633 (2002).
  • Ho DD. Time to hit HIM early and hard. N Engl. J. Med. 333,450–451 (1995).
  • Oxenius A, Hirschel B. Structured treatment interruptions in HIV infection: benefit or disappointment? Expert Rev. Anti-infect. Then 1, 129–139 (2003).
  • Cascade Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med. 1,224–231(2000).
  • Law M, Friis-Moller N, Weber R, et al Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of AntiHIV Drugs (DAD) study. HIV Med. 4,1–10 (2003).
  • Friis-Moller N, Weber R, Reiss P, et al Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17,1179–1193 (2003).
  • Fgger M, May M, Chene G, et al Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Larzcet 360, 119–129 (2002).
  • Fgger M, Chene G, Steme JA, et al Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362,679–686 (2003).
  • Yerly S, Kaiser L, Pemeger TV, et al Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 14,243–249 (2000).
  • Phillips AN, Staszewski S. Weber R, et al
  • Florence E, Lundgren J, Dreezen C, et al Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 4,255–262
  • Easterbrook PJ, Keruly JC, Creagh-Kirk T
  • Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15,1115–1123 (2001).
  • Chiesi A, Mocroft A, Dally LG, et al Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS 13,2281–2288 (1999).
  • Mocroft A, Phillips AN, Friis-Moller N, et al Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antiviral Then 7,21–30 (2002).
  • Palella Jr FJ, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 16,1617–1626 (2002).
  • Phillips AN, Grabar S, Tassie JM, et al Use of observational databases to evaluate the effectiveness of antiretroviral therapy for H[V infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 13,2075–2082 (1999).
  • Erb P, Battegay M, Zimmerli W, Rickenbach M, Fgger M. Effect of antiretroviral therapy on viral load, CD4 cell count and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss H[V Cohort Study. Arch Intern Med. 160,1134–1140 (2000).
  • Friedl AC, Ledergerber B, Flepp M, et al Response to first protease inhibitor-and efavirenz-containing antiretroviral combination therapy. The Swiss H[V Cohort Study. AIDS 15,1793–1800 (2001).
  • Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 15,1679–1686 (2001).
  • Staszewski S, Morales-Ramirez J, Tashima KT, et al Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of EITV-1 infection in adults. N. Eng/. J. Med. 341,1865–1873 (1999).
  • Phillips AN, Pradier C, Lazzarin A, et al Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 15,2385–2395 (2001).
  • Matthews GM, Sabin CA, Mandalia S, et al Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 16,53–61 (2002).
  • Cozzi-Lepri AAN, d'Arminio Monforte A, Phillips , et al Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.NA) study. Infect. Dis. 185, 1062–1069 (2002).
  • van Leth F, Other AN, Other AN, Other AN, Other AN. Results of the 2NN study: a randomized comparative trial of first—line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined together with stavudine and lamivudine. Tenth conference on Retroviruses Opportunistic Infect. (2003) (Abstract 176).
  • Mocroft A, Vella S, Benfield TL, et al Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Larzcet 352, 1725–1730 (1998).
  • Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13, 1933–1942 (1999).
  • Paklla Jr FJ, Delaney KM, Moorman AC, et al Declining mortality and morbidity in HIV-infected ambulatory patients. N Engl J. Med 328,853–860 (1998).
  • Mocroft A, Ledergerber B, Katlama C, et al Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362,22–29 (2003).
  • Cascade Collaboration. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS 14, 1899–906 (2000).
  • van Sighem AI, Van de Wiel MA, Ghani AC, et al Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 17, 2227–2236 (2003).
  • Palella Jr FJ, Knoll MD, Chmiel JS, et al Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138,620–626 (2003).
  • Carr A, Samaras K, Burton S, et al A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51—F58 (1998).
  • Periard D, Telenti A, Sudre P, et al Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100,700–705(1999).
  • Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160,2050–2056 (2000).
  • Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-1999. HIV Med. 2,84–8 (2001).
  • Lichtenstein KA, Ward DJ, Moorman AC, et al Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389-1398(2001).
  • Holmberg SD, Moorman AC, Williamson JM, et al Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Larzcet 360,1747–1748 (2002).
  • Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune DOc. Syrzdr. 30,471–477 (2002).
  • Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engli Med 348,702–710 (2003).
  • Coplan PM, Nikas A, Japour A, et al Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different proteaseinhibitors. AIDS Res. Hum. Retroviruses 19, 449–455(2003).
  • Becker SL, Raffanti SR, Hansen NI, et al Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J. Acquir. Immune DOc. Syrzdr. 26,72–81 (2001).
  • Phillips AN, Grabar S, Tassie J, et al Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 13, 2075–2082 (1999).
  • Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of NNRTI-containing and PI-containing regimens using observational databases. AIDS 15,1133–1142 (2001).
  • Raboud JM, Montaner JS, Thorne A, Singer J, Schechter MT. Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group. J. Acquir. Immune DOc. Syrzdr. 12,46–55 (1996).
  • Twisk J, de Vente W Attrition in longitudinal studies: How to deal with missing data. J. Cli,z. Epidemiol. 55, 329–337 (2002).
  • Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Impact of missing data due to selective dropouts in cohort studies and clinical trials. Epidemiology 13,347–355 (2002).
  • King JT, Jr., Justice AC, Roberts MS, Chang CC, Fusco JS. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis. Making 23,9–20 (2003).
  • Moorman AC, Holmberg SD, Marlowe SI, et al Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV out-patient study (HOPS). Ann. Epidemiol 9,349–357 (1999).
  • Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, et al When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 15,983–990 (2001).
  • Mandalia S, Parmar D, Fisher M, et al aively changing HAART. HIV Med. 3, 254–262 (2002).

Websites

  • StatEpi Coordinating Center Department of Epidemiology www.statepijhsph.edu/macs/macs.html Accessed November 2003
  • Clinical Trials Unit: Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) www.ctu.mrc.ac.uk/cascade/ Accessed November 2003
  • The National Centre in HIV Epidemiology and Clinical Research www.med.unsw.edu.au/nchecr Accessed November 2003
  • The BC Centre for Excellence in HIV/AIDS http://cfeweb.hivnet.ubc.ca/ Accessed November 2003
  • HIV Monitoring Foundation www.hiv-monitoring.n1 Accessed November 2003
  • Copenhagen HIV Programme www.cphiv.dk/eurosida/ Accessed November 2003
  • CDC www2a.cdc.gov/hops/ Accessed November 2003
  • The Ontario HIV Treatment Network: HIV Information Infrastructure Program (HIIP) www.ohm.on.ca/hood_index.html Accessed November 2003
  • The Johns Hopkins Center for AIDS Research www.hopkinsmedicine.org/aidsresearch Accessed November 2003
  • The Swiss HRT Cohort Study www.shcs.ch/ Accessed November 2003
  • Centre for Clinical Immunology and Biomedical Statistics www.maths.murdoch.edu.au/ccibs Accessed November 2003

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.